Five strategies for CAR-T pricing and reimbursement success

CAR-T therapy: the future begins to take shape

High expectations have been built up around the pricing, reimbursement, and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies based on the novel mechanism of action and trial results that indicate curative potential for a large segment of the treatable population. However, CAR-T represents an entirely new way of delivering cancer therapy, with significant challenges for manufacturers and healthcare systems.

This eBook provides: 

  • overviews of pricing and reimbursement of CAR‐T in France, Germany, and the UK
  • a summary of five key issues that are emerging from early regulatory,
  • pricing, and reimbursement decisions
    five strategies for success that manufacturers could consider.

FREE EBOOK

Free download

Latest insights

PRMA Consulting announces its new office opening ...

Transform your market access in Asia-Pacific: a ...

PRMA Healthcheck® for assets in ...